Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

Assets

Current assets:

Cash and cash equivalents $75,963 $87,905

Short-term investments 357,531 202,008

Trade accounts receivable, net of

allowance for doubtful accounts of

$719 and $670 at December 31, 2007

and December 31, 2006, respectively 32,678 25,880

Accounts receivable - other 11,044 1,646

Inventories 48,540 52,056

Deferred income tax - short term 8,825 7,247

Prepaid income tax 2,390 -

Prepaid expenses 17,505 11,362

Other current assets 4,402 2,583

Total current assets 558,878 390,687

Property, plant and equipment, net 129,493 134,614

Capitalized software 15,923 18,437

Goodwill 18,621 18,621

Deferred income tax - long term 7,942 2,064

License, manufacturing access fees and

other assets 58,196 59,416

Total assets $789,053 $623,839

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $11,777 $13,586

Accrued salaries and employee benefits 20,997 16,723

Other accrued expenses 4,014 3,320

Income tax payable 846 14,075

Deferred revenue 2,836 921

Total current liabilities 40,470 48,625

Non-current income tax payable
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Designation Process and Saves Lives, HARRISBURG, Pa., Aug. ... Web portal that will enable individuals to,sign up as ... driver,s,license or photo ID card is up for renewal ... Web portal, http://www.donatelife-pa.org, will link visitors to ...
... - Despite outcome, CEO Mark McDade to resign ... 20 PDL BioPharma, Inc.,(PDL) (Nasdaq: PDLI ... the company,s chief executive officer (CEO), Mark McDade,found ... breach of,fiduciary duty by McDade to corroborate the ...
... Fisher,Scientific Inc. (NYSE: TMO ) announced today ... and chief executive,officer, are adopting stock- trading programs ... the future sale of company stock. Mr.,Dekkers, who ... August,15-17, 2007, has adopted a plan for the ...
Cached Biology Technology:Web Portal Makes Organ Donation Easy 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 2PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 3PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty 4Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 /PRNewswire-USNewswire/ ... efforts to make it easier to detect and ... chain. Today the agency started performing ... The capability will validate the authenticity of purchased ... chain. The new quality control measures will be ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... April 2009 A major effort from within ... of an exceptional supplement by the Elsevier journal ... ). The supplement provides extensive studies based on ... niger and Aspergillus nidulans. The publication was enabled ...
... suffer medical complications from hypodermic needles that penetrate too ... MIT engineers and colleagues aims to prevent this from ... which is purely mechanical, is based on concepts borrowed ... needle containing a filament that acts as a guide ...
... down the constituent of olive oil that gives greatest protection ... major antioxidants in olive oil, Portuguese researchers showed that one, ... other part of olive oil. "These findings provide the ... seen in people who have olive oil in their diet," ...
Cached Biology News:MIT: Novel needle could cut medical complications 2
... RNasin Ribonuclease Inhibitors have broad spectrum RNase ... RNases of the neutral type (1). The ... noncovalently binding to RNases in a 1:1 ... of RNasin Ribonuclease Inhibitor to RNase (e.g., ...
... nucleic acids ,The GC-RICH PCR System, ... a proofreading polymerase, powers through templates that ... other polymerases and other blends of polymerases. ... the unique GC-RICH Resolution Solution combine to ...
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
B-FABP (FL-132)...
Biology Products: